GuidelineInternational journal of clinical oncology2024
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
Guideline in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Quality indicators of supportive care for patients with cancer undergoing treatment: a systematic review.BMC cancer · 2025Pooled it
- Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.International journal of clinical oncology · 2024Pooled it
- Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.International journal of clinical oncology · 2024Pooled it
- Clinical benefit and economic value of fosnetupitant versus aprepitant in carboplatin-Based chemotherapy: a real-world study.International journal of clinical oncology · 2026Article
- Potentially preventable unplanned hospitalizations due to adverse events in patients receiving systemic anticancer therapy: a retrospective single-center study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Prediction of chemotherapy-induced nausea during irinotecan-based treatment based on prior oxaliplatin-induced symptoms in colorectal cancer.International journal of clinical oncology · 2026Article
- Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N).Cancer chemotherapy and pharmacology · 2026Observational
- Web questionnaire survey of physicians and patients on the side effects of trifluridine/tipiracil.Scientific reports · 2026Article
- Postoperative nausea and vomiting as a predictor of chemotherapy-induced nausea and vomiting in gynecologic cancer: a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Article
- Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and Olanzapine.JMIR research protocols · 2026Observational
- Impact of baseline regular magnesium oxide administration on chemotherapy-induced constipation during cisplatin-containing treatment.International journal of clinical oncology · 2026Article
- Sustained antiemetic efficacy of fosnetupitant versus aprepitant in carboplatin-based chemotherapy: a retrospective observational study.International journal of clinical oncology · 2026Observational
- Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment.Scientific reports · 2026Article
- Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy.BMC cancer · 2026Observational
- Safety of Short-T erm Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study.Drug design, development and therapy · 2026Article
- Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.Journal of pharmaceutical health care and sciences · 2025Article
- Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists.International journal of clinical oncology · 2025Article
- Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy.International journal of clinical oncology · 2025Observational
- Evaluation of factors associated with drug fever following gemcitabine and nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens.
methodsGuided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020.
resultsComprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated.
conclusionsThe primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.